ATE254614T1 - Tetrahydro-benzo(d)azepine und deren verwendung als metabotrope glutamatrezeptor-antagonisten - Google Patents

Tetrahydro-benzo(d)azepine und deren verwendung als metabotrope glutamatrezeptor-antagonisten

Info

Publication number
ATE254614T1
ATE254614T1 AT00116091T AT00116091T ATE254614T1 AT E254614 T1 ATE254614 T1 AT E254614T1 AT 00116091 T AT00116091 T AT 00116091T AT 00116091 T AT00116091 T AT 00116091T AT E254614 T1 ATE254614 T1 AT E254614T1
Authority
AT
Austria
Prior art keywords
glutama
azepines
metabotropic
benzo
tetrahydro
Prior art date
Application number
AT00116091T
Other languages
English (en)
Inventor
Geo Adam
Alfred Binggeli
Hans-Peter Maerki
Vincent Mutel
Maurice Wilhelm
Wolfgang Wostl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE254614T1 publication Critical patent/ATE254614T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AT00116091T 1999-08-06 2000-07-27 Tetrahydro-benzo(d)azepine und deren verwendung als metabotrope glutamatrezeptor-antagonisten ATE254614T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99115557 1999-08-06

Publications (1)

Publication Number Publication Date
ATE254614T1 true ATE254614T1 (de) 2003-12-15

Family

ID=8238742

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00116091T ATE254614T1 (de) 1999-08-06 2000-07-27 Tetrahydro-benzo(d)azepine und deren verwendung als metabotrope glutamatrezeptor-antagonisten

Country Status (27)

Country Link
US (1) US6218385B1 (de)
JP (1) JP3260350B2 (de)
KR (1) KR100390116B1 (de)
CN (1) CN1146455C (de)
AR (1) AR025035A1 (de)
AT (1) ATE254614T1 (de)
AU (1) AU774485B2 (de)
BR (1) BR0003375A (de)
CA (1) CA2314798A1 (de)
CO (1) CO5180625A1 (de)
DE (1) DE60006618T2 (de)
ES (1) ES2209728T3 (de)
HR (1) HRP20000520A2 (de)
HU (1) HUP0003112A3 (de)
ID (1) ID26743A (de)
IL (1) IL137688A0 (de)
MA (1) MA26748A1 (de)
NO (1) NO20003966L (de)
NZ (1) NZ506096A (de)
PE (1) PE20010467A1 (de)
PL (1) PL341890A1 (de)
RU (1) RU2240317C2 (de)
SG (1) SG93251A1 (de)
TR (1) TR200002298A3 (de)
UY (1) UY26276A1 (de)
YU (1) YU49700A (de)
ZA (1) ZA200003927B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE297734T1 (de) * 2000-12-22 2005-07-15 Hoffmann La Roche Tetrahydro-(benzo- oder thieno-)azepin-pyrazin und triazinderivative als mglur 1 antagonisten
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
PT1572215E (pt) 2002-12-20 2009-12-09 Glaxo Group Ltd Derivados de benzo[d]azepina para o tratamento de perturbações neurológicas
CN1805938B (zh) * 2003-06-17 2010-06-16 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
US8367657B2 (en) * 2003-06-17 2013-02-05 Arena Pharmaceuticals, Inc. Processes for preparing 3-benzazepines
WO2005042491A1 (en) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
WO2005042490A1 (en) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
EP2149562A1 (de) 2004-12-21 2010-02-03 Arena Pharmaceuticals, Inc. Verfahren zur Herstellung des (R)-8-Chlor-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepinhydrochlorid-Hemihydrat
NZ589951A (en) * 2004-12-23 2012-11-30 Arena Pharm Inc 5HT2C receptor modulator compositions and methods of use
EP2275096A3 (de) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
EP2258357A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2646044A1 (en) 2006-04-03 2007-10-25 Arena Pharmaceuticals, Inc. Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto
EP2021000A2 (de) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP1873527A1 (de) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Verfahren zur Identifizierung von CRMP-Modulatoren
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
DK2083811T3 (en) 2006-11-22 2017-01-30 Clinical Res Ass Llc PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM
EP2099743B1 (de) * 2006-12-05 2014-08-27 Arena Pharmaceuticals, Inc. Verfahren zur herstellung von (r)-8-chlor-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepin und zwischenprodukten davon
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US8822727B2 (en) 2008-03-04 2014-09-02 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2010148207A2 (en) 2009-06-18 2010-12-23 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-ht2c receptor agonists
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2011153206A1 (en) 2010-06-02 2011-12-08 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-ht2c receptor agonists
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
KR20180118801A (ko) 2010-09-01 2018-10-31 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리에 유용한 5-ht2c 작동제의 변형-방출 투여 형태
EA201390335A1 (ru) 2010-09-01 2013-09-30 Арена Фармасьютикалз, Инк. Введение лоркасерина индивидуумам с почечной недостаточностью
KR20130101524A (ko) 2010-09-01 2013-09-13 아레나 파마슈티칼스, 인크. 5-ht2c 아고니스트의 비-흡습성 염
JP2013539470A (ja) 2010-09-01 2013-10-24 アリーナ ファーマシューティカルズ, インコーポレイテッド ロルカセリンと光学活性な酸との塩
RU2674670C1 (ru) 2012-10-09 2018-12-12 Арена Фармасьютикалз, Инк. Способ коррекции массы тела

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206210A (en) * 1977-01-19 1980-06-03 Smithkline Corporation Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity
BR9107070A (pt) * 1990-11-06 1994-05-31 Pfizer Processo para a preparação de derivados de quinazolina uteis para melhorar a atividade antitumoral.
US5241065A (en) * 1992-02-25 1993-08-31 Schering Corporation 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors

Also Published As

Publication number Publication date
NZ506096A (en) 2002-08-28
ID26743A (id) 2001-02-08
US6218385B1 (en) 2001-04-17
HRP20000520A2 (en) 2001-06-30
CO5180625A1 (es) 2002-07-30
HUP0003112A2 (hu) 2002-11-28
AR025035A1 (es) 2002-11-06
ES2209728T3 (es) 2004-07-01
AU4897900A (en) 2001-02-08
DE60006618T2 (de) 2004-09-23
HUP0003112A3 (en) 2003-07-28
RU2240317C2 (ru) 2004-11-20
IL137688A0 (en) 2001-10-31
PE20010467A1 (es) 2001-04-17
YU49700A (sh) 2003-04-30
NO20003966L (no) 2001-02-07
TR200002298A2 (tr) 2001-03-21
BR0003375A (pt) 2001-03-13
NO20003966D0 (no) 2000-08-04
CN1146455C (zh) 2004-04-21
JP3260350B2 (ja) 2002-02-25
HU0003112D0 (en) 2000-10-28
AU774485B2 (en) 2004-07-01
CN1283623A (zh) 2001-02-14
JP2001089472A (ja) 2001-04-03
MA26748A1 (fr) 2004-12-20
PL341890A1 (en) 2001-02-12
KR100390116B1 (ko) 2003-07-04
UY26276A1 (es) 2000-10-31
ZA200003927B (en) 2001-02-06
SG93251A1 (en) 2002-12-17
TR200002298A3 (tr) 2001-03-21
DE60006618D1 (de) 2003-12-24
CA2314798A1 (en) 2001-02-06
KR20010082510A (ko) 2001-08-30

Similar Documents

Publication Publication Date Title
DE60006618D1 (de) Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten
ATE261945T1 (de) Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
ATE250039T1 (de) Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
DE60015296D1 (de) Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
DE69925730D1 (de) 4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten
ATE496032T1 (de) 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
DE60114413D1 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
DE60112322D1 (de) Aminothiazole und deren verwendung als adenosinrezeptorantagonisten
EP1105389A4 (de) Integrinreceptorantagonisten
DE60106607D1 (de) Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
ATE280158T1 (de) 3-phenylpyridinderivative und deren verwendung als nk-1 rezeptorantagonisten
HUP0301665A3 (en) Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
DK1147115T5 (da) Tricycliske benzodiazepiner som vasopressinreceptorantagonister
EP1007051A4 (de) Integrin rezeptor antagonisten
HUP0303081A3 (en) Thrombin receptor antagonists, pharmaceutical compositions containing them and their use
EP1194151A4 (de) Antagonisten der integrin rezeptoren
EP1229910A4 (de) Integrinrezeptorantagonisten
AU9259801A (en) Alpha v integrin receptor antagonists
EP1027337A4 (de) Integrin-rezeptor-antagonisten
GB9820014D0 (en) Receptor antagonists and uses thereof
EP1248607A4 (de) Urotensin-ii rezeptorantagonisten
IL148043A0 (en) Novel integrin receptor antagonists
DE60126614D1 (de) 1,4-diazepan-2,5-dion-derivate und deren verwendung als nk-1 rezeptorantagonisten
IL146146A0 (en) Integrin receptor antagonists
AU5572500A (en) Vegf receptor antagonists

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1074549

Country of ref document: EP

REN Ceased due to non-payment of the annual fee